Federal Circuit Upholds Zomig Patents Finding Intranasal Delivery Not Obviousness

In Impax Laboratories Inc. v. Lannett Holdings Inc., the Federal Circuit upheld the district court decision finding that defendants had failed to establish obviousness of AstraZeneca’s Zomig patents (directed to intranasal zolmitriptan formulations).

https://www.natlawreview.com/article/federal-circuit-upholds-zomig-patents-finding-intranasal-delivery-not-obviousness